Valuation: Sareum Holdings plc

Market Cap 24.95M 33.41M 29.93M 27.56M 46.68M 3.17B 47.51M 328M 131M 1.67B 125M 123M 5.26B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 23.95M 32.07M 28.73M 26.45M 44.81M 3.05B 45.61M 315M 126M 1.6B 120M 118M 5.05B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 week-44.55%
Current month-50.81%
1 month-50.00%
3 months-27.38%
6 months-27.38%
Current year+1.67%
1 week 14
Extreme 14
18
1 month 14
Extreme 14
32
Current year 13
Extreme 13
40
1 year 11.75
Extreme 11.75
40
3 years 9.5
Extreme 9.5
78
5 years 9.5
Extreme 9.5
345
10 years 9.5
Extreme 9.5
500
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 2003-07-31
Chief Executive Officer 65 2003-07-31
Corporate Secretary 72 2018-11-12
Director TitleAgeSince
Director/Board Member 65 2010-11-10
Director/Board Member 58 2010-11-10
Chairman 67 2016-05-16
Date Insider Type Main position Quantity % Market Cap. Importance
3/27/25 Buy

Chairman

84,033 0.0673%
11/8/23 Sell 72,000 0.1025%
11/8/23 Sell 50,426 0.0718%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-44.55%+12.96%-76.54% 33.37M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.09%+4.25%+48.89%+140.08% 39.27B
Weighted average by Cap. +0.02%+3.64%+49.57%+162.45%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt -1M -1.34M -1.2M -1.1M -1.87M -127M -1.9M -13.15M -5.27M -66.87M -5.02M -4.92M -211M -
Projected Income Statement - Annual - Sareum Holdings plc
Logo Sareum Holdings plc
Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Employees
5
Date Price Change Volume
26-10-30 GBX 15.25 0.00% 198,705
26-10-29 GBX 15.25 -7.58% 899,446
26-10-28 GBX 16.50 +1.54% 318,329
26-10-27 GBX 16.25 -1.52% 802,405
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1525GBP
Average target price
0.4160GBP
Spread / Average Target
+172.79%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Sareum Holdings plc